Karyopharm Therapeutics (KPTI) Change in Cash (2012 - 2025)

Karyopharm Therapeutics has reported Change in Cash for 14 years, with the latest figure at $22.9 million in Q4 2025.

• For the quarter ending Q4 2025, Change in Cash rose 320.89% year-over-year to $22.9 million; the trailing twelve-month figure through Dec 2025 stood at -$1.9 million (down 119.99% YoY), and the FY2025 full-year result was -$1.9 million, down 119.99% from the prior year.
• Change in Cash for Q4 2025 stood at $22.9 million, up from -$1.1 million in the prior quarter.
• The five-year high for Change in Cash was $63.8 million in Q4 2022, with the low at -$70.9 million in Q2 2022.
• Historically, Change in Cash has averaged -$1.4 million across 5 years, with a median of -$3.0 million in 2021.
• Annual changes were most pronounced in 2022 — Change in Cash sank 4917.55% — and 2024, when it jumped 1554.22%.
• Karyopharm Therapeutics' Change in Cash stood at $57.0 million in 2021, then rose by 11.97% to $63.8 million in 2022, then slumped by 86.51% to $8.6 million in 2023, then sank by 220.23% to -$10.4 million in 2024, then soared by 320.89% to $22.9 million in 2025.
• The last three Change in Cash figures came in at $22.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$48000.0 (Q2 2025), per Business Quant data.